Other substances

Dabigatran etexilate

A thrombin inhibitor prodrug.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Used to treat other disease

1
 Supporting references
0
 Contradictory references
1
 AI-suggested references
0
 Clinical trials

General information

Dabigatran etexilate on PubChem

Marketed as

DABIGATRAN ETEXILATE; PRADAX; PRADAXA; RENDIX

 

Structure image - Dabigatran etexilate

CCCCCCOC(=O)NC(=N)C1=CC=C(C=C1)NCC2=NC3=C(N2C)C=CC(=C3)C(=O)N(CCC(=O)OCC)C4=CC=CC=N4

Supporting references

Link Tested on Impact factor Notes Publication date
In silico identification of drug candidates against COVID-19
3CLpro RdRpol 		in silico 2.11

Predicted to inhibit the SARS-CoV-2 3C-like protease.

 Oct/20/2020

AI-suggested references

Link Publication date
Azolo[1,5-a]pyrimidines and Their Condensed Analogs with Anticoagulant Activity
Jan/02/2022
Export (.csv)